ECSP10010473A - Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización - Google Patents

Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización

Info

Publication number
ECSP10010473A
ECSP10010473A EC2010010473A ECSP10010473A ECSP10010473A EC SP10010473 A ECSP10010473 A EC SP10010473A EC 2010010473 A EC2010010473 A EC 2010010473A EC SP10010473 A ECSP10010473 A EC SP10010473A EC SP10010473 A ECSP10010473 A EC SP10010473A
Authority
EC
Ecuador
Prior art keywords
alkyl
optionally substituted
hsp90
carbazol
inhibitors
Prior art date
Application number
EC2010010473A
Other languages
English (en)
Inventor
Franck Halley
Jean-Marie Ruxer
Patrick Mailliet
Luc Bertin
Herve Minoux
Maria Mendez-Perez
Marcel Alasia
Victor Certal
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010473(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP10010473A publication Critical patent/ECSP10010473A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Abstract

La invención se refiere a nuevos productos de fórmula (I): en los que Het representa un heterociclo opcionalmente sustituido por uno o varios radicales R1 o R'1, R se elige del grupo constituido por Fórmula (II) con R1 y/o R'1, elegidos entre: H, halógeno, CF3, nitro, ciano, alquilo, hidroxi, mercapto, amino, alquilamino, dialquilamino, alcoxi, fenilalcoxi, alquiltio, carboxi libre o esterificado por un radical: alquilo, carboxamida, CO-NH(alquilo), CON(alquilo)2, NH-CO-alquilo, sulfonamida, NH-SO2-alquilo, S(O)2-NHalquilo, S(O2)-N(alquilo)2; todos estos radicales opcionalmente sustituidos; W1, W2, W3 representan independientemente CH o N, X representa: O, S, NR2, C(O), S(O) o S(O)2; Z representa: H, Hal, -O-R2 o -NH-R2 donde R2 representa: H, alquilo, cicloalquilo o heterocicloalquilo opcionalmente sustituidos; estando estos productos en todas las formas isómeras y las sales, como medicamentos.
EC2010010473A 2008-03-14 2010-09-10 Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización ECSP10010473A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801394A FR2928645A1 (fr) 2008-03-14 2008-03-14 Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
ECSP10010473A true ECSP10010473A (es) 2010-10-30

Family

ID=39930567

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010473A ECSP10010473A (es) 2008-03-14 2010-09-10 Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización

Country Status (24)

Country Link
US (1) US8309721B2 (es)
EP (1) EP2265598A2 (es)
JP (1) JP5674483B2 (es)
KR (1) KR20100130603A (es)
CN (1) CN102026992A (es)
AR (1) AR070836A1 (es)
AU (1) AU2009232121A1 (es)
BR (1) BRPI0909731A2 (es)
CA (1) CA2718488A1 (es)
CL (1) CL2009000619A1 (es)
CO (1) CO6251295A2 (es)
CR (1) CR11653A (es)
DO (1) DOP2010000272A (es)
EA (1) EA201071078A1 (es)
EC (1) ECSP10010473A (es)
FR (1) FR2928645A1 (es)
IL (1) IL208059A0 (es)
MA (1) MA32206B1 (es)
MX (1) MX2010010018A (es)
NI (1) NI201000150A (es)
PE (1) PE20091673A1 (es)
TW (1) TW200938541A (es)
UY (1) UY31711A (es)
WO (1) WO2009122034A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035416A1 (en) * 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Hsp90 modulating compounds, compositions, methods and uses
AU2012204651A1 (en) * 2011-01-07 2013-08-01 Taiho Pharmaceutical Co., Ltd. Novel bicyclic compound or salt thereof
KR20140025326A (ko) 2011-01-07 2014-03-04 다이호야쿠힌고교 가부시키가이샤 신규 인돌, 인다졸 유도체 또는 그 염
JP5842630B2 (ja) * 2011-03-16 2016-01-13 株式会社リコー カルバゾール誘導体、及び半導体ナノ結晶
JP2014075556A (ja) * 2012-10-05 2014-04-24 Idemitsu Kosan Co Ltd 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
ES2723888T3 (es) 2013-01-10 2019-09-03 Merck Patent Gmbh Piperidinilcarbazol como antipalúdico
US10150728B2 (en) 2013-10-17 2018-12-11 Shionogi & Co., Ltd. Alkylene derivatives
WO2015084998A1 (en) 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20170158636A1 (en) * 2014-07-16 2017-06-08 Novogen Ltd. Functionalised and substituted carbazoles as anti-cancer agents
AU2015326920A1 (en) * 2014-10-01 2017-03-02 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indoles as dengue viral replication inhibitors
JOP20150335B1 (ar) * 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2016176571A1 (en) * 2015-04-29 2016-11-03 Arena Pharmaceuticals, Inc. 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
DE102016122122B4 (de) * 2015-11-18 2021-02-11 Cynora Gmbh Organische Moleküle, insbesondere zur Verwendung in organischen optoelektronischen Vorrichtungen
US9966542B2 (en) * 2016-06-02 2018-05-08 E I Du Pont De Nemours And Company Electroactive materials
DE102017008073A1 (de) * 2017-08-28 2019-02-28 Henkel Ag & Co. Kgaa Neue anionische Tenside und Wasch- und Reinigungsmittel, welche diese enthalten
CN111217741B (zh) * 2019-03-01 2022-03-15 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 氟取代单咔唑类衍生物、其制备方法及应用
WO2023208092A1 (en) * 2022-04-28 2023-11-02 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
CN117159570B (zh) * 2023-11-01 2024-01-23 云南中医药大学 6-酰氧基甘露糖叠氮乙苷衍生物与氟康唑联合在制备抗耐药白念珠菌药物中的应用
CN117486782A (zh) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 一种n-取代咔唑衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317926B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Derivati triciclici dell'indolo ad attivita' antiangiogenica.
CN101072759B (zh) * 2004-11-18 2013-06-19 Synta医药公司 调节hsp90活性的三唑化合物
JP2009508872A (ja) * 2005-09-16 2009-03-05 セレネックス， インコーポレイテッド カルバゾール誘導体
US8405508B2 (en) 2006-08-09 2013-03-26 Emd Millipore Corporation Use of gamma hardened RFID tags in pharmaceutical devices

Also Published As

Publication number Publication date
CN102026992A (zh) 2011-04-20
IL208059A0 (en) 2010-12-30
JP2011513473A (ja) 2011-04-28
PE20091673A1 (es) 2009-11-14
AU2009232121A1 (en) 2009-10-08
WO2009122034A3 (fr) 2009-12-03
FR2928645A1 (fr) 2009-09-18
CL2009000619A1 (es) 2011-02-18
US8309721B2 (en) 2012-11-13
UY31711A (es) 2009-11-10
KR20100130603A (ko) 2010-12-13
TW200938541A (en) 2009-09-16
CA2718488A1 (fr) 2009-10-08
CR11653A (es) 2010-11-22
MX2010010018A (es) 2010-12-15
MA32206B1 (fr) 2011-04-01
BRPI0909731A2 (pt) 2019-03-06
EP2265598A2 (fr) 2010-12-29
AR070836A1 (es) 2010-05-05
US20110166169A1 (en) 2011-07-07
NI201000150A (es) 2011-03-29
DOP2010000272A (es) 2010-10-15
CO6251295A2 (es) 2011-02-21
JP5674483B2 (ja) 2015-02-25
EA201071078A1 (ru) 2011-04-29
WO2009122034A8 (fr) 2010-08-19
WO2009122034A2 (fr) 2009-10-08

Similar Documents

Publication Publication Date Title
ECSP10010473A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
CY1112102T1 (el) Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1
UY30105A1 (es) Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas.
AR088352A1 (es) Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos
MX2011009806A (es) Nuevos derivados de indazol inhibidores de hsp90, composiciones que los contienen y su uso.
CL2012000003A1 (es) Compuestos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida sustituida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y uso de dichos compuestos como inhibidores de fosforilacion de akt (pkb) para el tratamiento del cancer.
AR093801A1 (es) Derivados de 1,4-ditiina sustituida y su uso como fungicidas
CO6160311A2 (es) Nuevos derivados de fluoreno composiciones que los contienen y utilizacion como inhibidores de la proteina chaperona hsp90
CO6280537A2 (es) Nuevos derivados de pirroloindol inhibidores de hsp90 composiciones que los contienen y utilizacion
CO6420339A2 (es) Derivados de 6-(6-sustituido-triazolopiridacina-sulfanil) 5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met
BR112013016637A2 (pt) processo para a preparação de derivados de 3-alquil-sulfinilbenzoíla